Safety profile with T-cell–redirecting therapies: immune-related adverse events, cytopenias, infections, and others
| . | CAR-Ts . | BiAbs . | P value . |
|---|---|---|---|
| Immune-related adverse events | |||
| CRS, n (%) | 33 of 36 (91.7) | 28 of 37 (75.7) | NS |
| CRS grade ≥3, n (%) | 0 of 36 (0.0) | 0 of 37 (0.0) | NS |
| ICANS, n (%) | 2 of 36 (5.6) | 3 of 37 (8.1) | NS |
| ICANS grade ≥3, n (%) | 1 of 36 (2.7) | 1 of 37 (2.7) | NS |
| IEC-HS, n (%) | 7 of 36 (19.4) | 0 of 37 (0.0) | .005 |
| IEC-HS grade ≥3, n (%) | 1 of 36 (2.8) | 0 of 37 (0.0) | NS |
| Cytopenias | |||
| Neutropenia grade 4, n (%) | 35 of 36 (97.2) | 7 of 37 (18.9) | <.001 |
| Neutropenia grade ≥3 | |||
| Early-term, n (%) | 34 of 36 (94.4) | 11 of 37 (29.7) | <.001 |
| Midterm, n (%) | 31 of 35 (88.6) | 12 of 31 (38.7) | < .001 |
| Late-term, n (%) | 14 of 35 (40.0) | 10 of 23 (43.5) | NS |
| Thrombocytopenia grade 4, n (%) | 26 of 36 (72.2) | 5 of 37 (13.5) | <.001 |
| Thrombocytopenia grade ≥3 | |||
| Early-term, n (%) | 26 of 36 (72.2) | 6 of 37 (16.2) | <.001 |
| Midterm, n (%) | 23 of 35 (65.7) | 3 of 31 (9.7) | <.001 |
| Late-term, n (%) | 9 of 35 (25.7) | 1 of 23 (4.3) | NS |
| Infections | |||
| Infections, n (%) | 27 of 36 (75.0) | 24 of 37 (64.9) | NS |
| Infections grade ≥3, n (%) | 10 of 36 (27.8) | 10 of 37 (27.0) | NS |
| Early-term infections, n (%) | 6 of 36 (16.7) | 7 of 37 (18.9) | NS |
| Midterm infections, n (%) | 10 of 35 (28.6) | 14 of 31 (45.2) | NS |
| Late-term infections, n (%) | 20 of 35 (57.1) | 17 of 23 (74.0) | NS |
| Others | |||
| Tumor lysis syndrome, n (%) | 2 of 36 (5.6) | 0 of 37 (0.0) | .146 |
| Hypogammaglobulinemia, n (%) | 30 of 35 (85.7) | 24 of 37 (64.9) | .047 |
| . | CAR-Ts . | BiAbs . | P value . |
|---|---|---|---|
| Immune-related adverse events | |||
| CRS, n (%) | 33 of 36 (91.7) | 28 of 37 (75.7) | NS |
| CRS grade ≥3, n (%) | 0 of 36 (0.0) | 0 of 37 (0.0) | NS |
| ICANS, n (%) | 2 of 36 (5.6) | 3 of 37 (8.1) | NS |
| ICANS grade ≥3, n (%) | 1 of 36 (2.7) | 1 of 37 (2.7) | NS |
| IEC-HS, n (%) | 7 of 36 (19.4) | 0 of 37 (0.0) | .005 |
| IEC-HS grade ≥3, n (%) | 1 of 36 (2.8) | 0 of 37 (0.0) | NS |
| Cytopenias | |||
| Neutropenia grade 4, n (%) | 35 of 36 (97.2) | 7 of 37 (18.9) | <.001 |
| Neutropenia grade ≥3 | |||
| Early-term, n (%) | 34 of 36 (94.4) | 11 of 37 (29.7) | <.001 |
| Midterm, n (%) | 31 of 35 (88.6) | 12 of 31 (38.7) | < .001 |
| Late-term, n (%) | 14 of 35 (40.0) | 10 of 23 (43.5) | NS |
| Thrombocytopenia grade 4, n (%) | 26 of 36 (72.2) | 5 of 37 (13.5) | <.001 |
| Thrombocytopenia grade ≥3 | |||
| Early-term, n (%) | 26 of 36 (72.2) | 6 of 37 (16.2) | <.001 |
| Midterm, n (%) | 23 of 35 (65.7) | 3 of 31 (9.7) | <.001 |
| Late-term, n (%) | 9 of 35 (25.7) | 1 of 23 (4.3) | NS |
| Infections | |||
| Infections, n (%) | 27 of 36 (75.0) | 24 of 37 (64.9) | NS |
| Infections grade ≥3, n (%) | 10 of 36 (27.8) | 10 of 37 (27.0) | NS |
| Early-term infections, n (%) | 6 of 36 (16.7) | 7 of 37 (18.9) | NS |
| Midterm infections, n (%) | 10 of 35 (28.6) | 14 of 31 (45.2) | NS |
| Late-term infections, n (%) | 20 of 35 (57.1) | 17 of 23 (74.0) | NS |
| Others | |||
| Tumor lysis syndrome, n (%) | 2 of 36 (5.6) | 0 of 37 (0.0) | .146 |
| Hypogammaglobulinemia, n (%) | 30 of 35 (85.7) | 24 of 37 (64.9) | .047 |
CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome; NS, not significant.